Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06172751 · ClinicalTrials.gov registry record
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
A clinical trial of Hypereosinophilic Syndrome (HES), sponsored by AstraZeneca.
- Completed
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT06172751: Completed study of Hypereosinophilic Syndrome (HES), sponsored by AstraZeneca.
NCT06172751 is a study of Hypereosinophilic Syndrome (HES) that has completed, run by AstraZeneca. The registered enrollment target is 250 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06172751, a study of Hypereosinophilic Syndrome (HES), has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.
Primary Outcome
To describe clinical characteristics of patients with HES.
Conditions Studied
Interventions
- OTHER no intervention
Study Locations (1)
Massachusetts
- Research Site - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2024-04-26 |
What the finished NCT06172751 record still lists
NCT06172751 is an observational study that tracks outcomes without assigning an intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Hypereosinophilic Syndrome (HES) appearing as the primary indexed condition, and to 1 intervention - of which no intervention is the first listed.
NCT06172751 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06172751 about?
NCT06172751 is a clinical study titled "TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause". The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.
What is the current status of trial NCT06172751?
This trial is currently completed. The enrollment target is 250 participants. The study started on 2023-12-15. Estimated completion is 2024-04-26.
What conditions does trial NCT06172751 study?
This clinical trial studies the following conditions: Hypereosinophilic Syndrome (HES).
What interventions are being tested in trial NCT06172751?
The interventions under investigation include: no intervention (OTHER).
Who is sponsoring clinical trial NCT06172751?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06172751 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI